Ryan, Isabelle and Long delve into the ever-changing world of cancer treatments. They discuss both targeted and non-targeted treatment strategies and what the future of cancer treatment may look like!
References
1. Voorhees P. Case Presentation: A 63-Year-Old Patient with Relapsed-Refractory (R/R) Multiple Myeloma [Internet]. Targeted Oncology. 2023. Available from: https://www.targetedonc.com/view/case-presentation-a-63-year-old-patient-with-relapsed-refractory-r-r-multiple-myeloma
2. Understanding What Cancer Is: Ancient Times to Present . Cancer.org. 2018. Available from: https://www.cancer.org/cancer/understanding-cancer/history-of-cancer/what-is-cancer.html#:~:text=Human%20beings%20and%20other%20animals,%E2%80%9CThere%20is%20no%20treatment.%E2%80%9D
3. Cancer in Australia statistics. Cancer Australia. 2022. Available from: https://www.canceraustralia.gov.au/research-data/data-and-statistics/cancer-australia-statistics
4. Cancer information and support [Internet]. Cancer.org.au. 2021. Available from: https://www.cancer.org.au/
5. What is Chemotherapy? | Chemo Treatment for Cancer [Internet]. Cancer.org. 2025.
6. Radiation therapy - Mayo Clinic [Internet]. Mayoclinic.org.; 2025.
7. Radiation Therapy for Cancer [Internet]. Cancer.gov. 2019.
8. Yasemin Ceyhan, Marie N, Alvarez JV. Immune cells in residual disease and recurrence. Trends in cancer [Internet]. 2023 May 5;9(7):554–65.
9. Lim ZF, Ma PC. Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy. Journal of Hematology & Oncology. 2019 Dec 1;12(1).
10. Gregory A. “Amazing” trial shows drug combination stops lung cancer advancing for longer [Internet]. The Guardian. The Guardian; 2024.
11. Xiang Y, Liu X, Wang Y, Zheng D, Meng Q, Jiang L, et al. Mechanisms of resistance to targeted therapy and immunotherapy in non-small cell lung cancer: promising strategies to overcoming challenges. Frontiers in Immunology [Internet]. 2024 Apr 9;15.
12. Personalized Medicine [Internet]. Genome.gov. 2025.
13. Rivera-Soto R, Henley B, Pulgar MA, Lehman SL, Gupta H, Perez-Vale KZ, et al. Amivantamab efficacy in wild-type EGFR NSCLC tumors correlates with levels of ligand expression. npj Precision Oncology [Internet]. 2024 Sep 6;8(1).
14. Immune Checkpoint Inhibitors [Internet]. Cancer.gov. 2022.
15. Liu L, Krishnan A. Talquetamab in multiple myeloma. Haematologica [Internet]. 2023 Oct 19 ;109(3):718–24.
16. Ma Y, Gan J, Bai Y, Cao D, Jiao Y. Minimal residual disease in solid tumors: an overview. Frontiers of Medicine [Internet]. 2023 Aug 1;17(4):649–74.
17. B Martínez-Castedo, Camblor DG, J Martín-Arana, Carbonell-Asins JA, B García-Micó, Gambardella V, et al. Minimal residual disease in colorectal cancer. Tumor-informed versus tumor-agnostic approaches: unraveling the optimal strategy. Annals of Oncology [Internet]. 2024
18. Peker YS, Can MF, Ismail Hakki Ozerhan, Gokhan Yagci, Nazif Zeybek, Kutan Kavakli, et al. BRAF Inhibitors for BRAF V600E Mutant Colorectal Cancers: Literature Survey and Case Report. Case Reports in Surgery [Internet]. 2018 Jan 1 ;2018:1–6.
19. Lim ZF, Ma PC. Emerging insights of tumor heterogeneity and drug resistance mechanisms in lung cancer targeted therapy. Journal of Hematology & Oncology [Internet]. 2019 Dec 1;12(1).
20. Ahn M, Tsai C, Shepherd FA, Lyudmila Bazhenova, Sequist LV, Hida T, et al. Osimertinib in patients with T790M mutation‐positive, advanced non–small cell lung cancer: Long‐term follow‐up from a pooled analysis of 2 phase 2 studies. Cancer [Internet]. 2018 Dec 4;125(6):892–901.
21. Siravegna G, Marsoni S, Siena S, Bardelli A. Integrating liquid biopsies into the management of cancer. Nature Reviews Clinical Oncology [Internet]. 2017 Mar 2;14(9):531–48.
22. DePolo J. Triple-Negative Breast Cancer (TNBC) [Internet]. Breastcancer.org. 2022 .
23. Beasley D. Gilead says Trodelvy-Keytruda combo effective for aggressive breast cancer type [Internet]. Reuters. 2025.